Alkem Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Midcap 150 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Vikas Gupta has resigned as Chief Executive Officer and Key Managerial Personnel of Alkem Laboratories effective April 24, 2026. He will continue in the role until June 30, 2026 to ensure a smooth transition of responsibilities. The stated reason for departure is to pursue new professional opportunities aligned with his long-term goals. Dr. Gupta served as CEO for several years, during which he oversaw the company's market position and R&D pipeline development. The resignation letter acknowledges the Promoter Family and Board of Directors for their leadership and support during his tenure. The company has not announced a successor as yet.
The sudden resignation of the CEO creates leadership uncertainty ahead of a planned transition. Investors will likely monitor for announcement of the new CEO, as the stock may experience volatility until a replacement is confirmed. The extended transition period of over two months suggests management stability is being prioritised.